Literature DB >> 1911191

Breast cancer proliferation measured on cytological samples: a study by flow cytometry of S-phase fractions and BrdU incorporation.

Y Remvikos1, P Vielh, E Padoy, B Benyahia, N Voillemot, H Magdelénat.   

Abstract

Cell kinetics have been shown to be an important predictor of clinical evolution of operated breast cancer. We established a method for the estimation of the proliferative activity of tumour cells obtained by fine needle sampling without aspiration (FNS), using simultaneously S-phase fractions (SPF) measured on DNA histograms and 5-bromodeoxyuridine (BrdU) labelling index (BLI) measured by flow cytometry. Biparametric BrdU/DNA flow cytometry could be performed in 122 of 189 (65%) consecutive patients. The mean BLI of the cytologically malignant FNS (118) was of 3.0 and the median of 2.2%. One hundred and forty-eight DNA histograms (78%) were suitable for SPF analysis, of which 141 presented malignant cells, showing a mean of 4.5 and a median of 3.5%, comparable to BLIs. These results were obtained from fluorescence peak area histograms with doublet discrimination and background subtraction allowing the measurements of SPFs as low as 0.4%. An excellent correlation was thus observed between BLIs and SPFs, for the 94 cases for which both results were available (r = 0.85). Infrequent discordances (9%) were noted with SPFs considerably higher than BLIs. Seven patients had three consecutive FNS of their tumour at weekly intervals before treatment. Some variability in the proportions of multiple subpopulations of tumour cells was observed on the DNA histograms. In contrast, proliferation indices (SPF or BLI) were reproducible, suggesting homogeneous growth rates. We conclude that an estimation of the proliferative activity of breast tumours at any stage of the disease is possible routinely by SPF and/or BLI analysis of FNS. At least one quantitative proliferation index could be obtained for 91% of patients.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1911191      PMCID: PMC1977653          DOI: 10.1038/bjc.1991.338

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  28 in total

1.  An improved method for the immunocytochemical detection of bromodeoxyuridine labeled nuclei using flow cytometry.

Authors:  B Schutte; M M Reynders; C L van Assche; P S Hupperets; F T Bosman; G H Blijham
Journal:  Cytometry       Date:  1987-07

2.  Comparative analysis of different approaches to investigate cell kinetics.

Authors:  R Silvestrini; A Costa; S Veneroni; G Del Bino; P Persici
Journal:  Cell Tissue Kinet       Date:  1988-03

3.  Sequential cytopunctures during preoperative chemotherapy for primary breast carcinoma. Cytomorphologic changes, initial tumor ploidy, and tumor regression.

Authors:  M Briffod; F Spyratos; M Tubiana-Hulin; C Pallud; C Mayras; A Filleul; J Rouëssé
Journal:  Cancer       Date:  1989-02-15       Impact factor: 6.860

Review 4.  Practical breast carcinoma cell kinetics: review and update.

Authors:  J S Meyer; R W McDivitt; K R Stone; M U Prey; W C Bauer
Journal:  Breast Cancer Res Treat       Date:  1984       Impact factor: 4.872

5.  Flow cytometric measurement of total DNA content and incorporated bromodeoxyuridine.

Authors:  F Dolbeare; H Gratzner; M G Pallavicini; J W Gray
Journal:  Proc Natl Acad Sci U S A       Date:  1983-09       Impact factor: 11.205

6.  Correlation of pretreatment proliferative activity of breast cancer with the response to cytotoxic chemotherapy.

Authors:  Y Remvikos; P Beuzeboc; A Zajdela; N Voillemot; H Magdelénat; P Pouillart
Journal:  J Natl Cancer Inst       Date:  1989-09-20       Impact factor: 13.506

7.  3H-thymidine incorporation into mammary carcinoma cells obtained by needle aspiration before and during endocrine therapy.

Authors:  B Nordenskjöld; T Löwhagen; H Westerberg; J Zajicek
Journal:  Acta Cytol       Date:  1976 Mar-Apr       Impact factor: 2.319

8.  Cell kinetic studies of in situ human brain tumors with bromodeoxyuridine.

Authors:  T Hoshino; T Nagashima; J Murovic; E M Levin; V A Levin; S M Rupp
Journal:  Cytometry       Date:  1985-11

9.  Variations associated with the DNA analysis of multiple fine needle aspirates obtained from breast cancer patients.

Authors:  P Mullen; W R Miller
Journal:  Br J Cancer       Date:  1989-05       Impact factor: 7.640

10.  Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years.

Authors:  H J BLOOM; W W RICHARDSON
Journal:  Br J Cancer       Date:  1957-09       Impact factor: 7.640

View more
  9 in total

1.  Flow Cytometric Assay of c-erbB-2 Protein in Fine Needle Aspirates of Fresh and Frozen Human Breast Cancer Tissues.

Authors: 
Journal:  Breast Cancer       Date:  1996-06-28       Impact factor: 4.239

Review 2.  Bromodeoxyuridine: a diagnostic tool in biology and medicine, Part II: Oncology, chemotherapy and carcinogenesis.

Authors:  F Dolbeare
Journal:  Histochem J       Date:  1995-12

3.  Potential tumour doubling time: determination of Tpot for various canine and feline tumours.

Authors:  U Schwyn; N E Crompton; H Blattmann; B Hauser; B Klink; A Parvis; D Ruslander; B Kaser-Hotz
Journal:  Vet Res Commun       Date:  1998-06       Impact factor: 2.459

4.  Inverse association of rab31 and mucin-1 (CA15-3) antigen levels in estrogen receptor-positive (ER+) breast cancer tissues with clinicopathological parameters and patients' prognosis.

Authors:  Matthias Kotzsch; Thomas Kirchner; Susanne Soelch; Sonja Schäfer; Katrin Friedrich; Gustavo Baretton; Viktor Magdolen; Thomas Luther
Journal:  Am J Cancer Res       Date:  2017-09-01       Impact factor: 6.166

5.  Proliferative activity of breast cancers increases in the course of genetic evolution as defined by cytogenetic analysis.

Authors:  Y Remvikos; M Gerbault-Seureau; H Magdelénat; M Prieur; B Dutrillaux
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

6.  Genetic evolution of breast cancers. III: Age-dependent variations in the correlations between biological indicators of prognosis.

Authors:  Y Remvikos; H Magdelenat; B Dutrillaux
Journal:  Breast Cancer Res Treat       Date:  1995-04       Impact factor: 4.872

7.  Plasminogen activator inhibitor-1 (PAI-1) is not related to response to neoadjuvant chemotherapy in breast cancer.

Authors:  J Y Pierga; C Lainé-Bidron; P Beuzeboc; P De Crémoux; P Pouillart; H Magdelénat
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

8.  Measurement of S-phase fraction and ploidy in sequential fine-needle aspirates from primary human breast tumours treated with tamoxifen.

Authors:  I N Fernando; J C Titley; T J Powles; M Dowsett; P A Trott; S E Ashley; H T Ford; M G Ormerod
Journal:  Br J Cancer       Date:  1994-12       Impact factor: 7.640

9.  Neural differentiation and synaptogenesis in retinal development.

Authors:  Wen-Juan Fan; Xue Li; Huan-Ling Yao; Jie-Xin Deng; Hong-Liang Liu; Zhan-Jun Cui; Qiang Wang; Ping Wu; Jin-Bo Deng
Journal:  Neural Regen Res       Date:  2016-02       Impact factor: 5.135

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.